Navigation Links
Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
Date:10/15/2007

the trial did not meet the primary endpoint, we are encouraged by the favorable trend seen in the subgroup of subjects receiving cholinesterase inhibitors," said Stephen R. Murray, M.D., Ph.D., Chief Medical Officer. "Clearly there is a significant need for new options for the treatment of Alzheimer's disease, and we believe that the effects of MEM 1003 seen in this study warrant further investigation."

Subjects participating in the study were randomized at enrollment into one of three treatment groups -- 30 mg of MEM 1003 twice a day, 90 mg of MEM 1003 twice a day or placebo twice a day. During the double-blind treatment segment of the study, subjects received MEM 1003 or placebo for a period of 12 weeks, which was followed by a four-week single-blind placebo treatment. Secondary measures assessed changes in activities of daily living, behavior and global function.

MEM 1003 was generally well-tolerated in the trial. The rates of treatment-emergent adverse events were similar in all arms of the trial. There were seven treatment-emergent serious adverse events (SAEs) in five subjects, including two deaths. Four of the subjects were in the 30 mg dose group and the fifth subject was in the 90 mg dose group. None of the SAEs were deemed to be treatment-related by the investigators.

The Company expects to report top-line results from its Phase 2a clinical trial of MEM 3454, its lead nicotinic alpha-7 agonist, in Alzheimer's disease by the middle of the fourth quarter.

About MEM 1003

MEM 1003 is a neuronal L-type calcium channel modulator that Memory Pharmaceuticals is developing for the treatment of Alzheimer's disease. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium and reestablish normal levels of calcium, which may help treat and prevent the onset of Alzheimer's disease.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on Monday, October 15, 2007, at 9:00
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Laboratory (IL) today announced the launch of its new corporate ... of a comprehensive rebranding effort by Werfen, the parent company ... , in 1959, IL has been part of the ... the group include Inova Diagnostics ( San Diego, CA ... ).  Like IL, these three companies are focused on ...
(Date:7/29/2014)... TORONTO , July 29, ... ESAQ), an emerging pharmaceutical company exploring drug ... novel formulations and alternative dosage forms of ... its pharmaceutical development implementing its sub-micron platform technology.  ... drugs that will address indications in diabetes ...
(Date:7/29/2014)... -- Research and Markets has announced the ... report to their offering. ... a medical device used to provide medication or assist ... cannot achieve adequate oxygen levels to maintain life. Patients ... and ARDS require the need of respiratory devices. The ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Global Respiratory Devices Market 2014-2018 2
... Food and Drug Administration (FDA) says children and pets should not come in contact with ... menopause. , , , ... , , ... , The agency also wants ...
... AUSTIN, Texas ,  July 29 Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics ... issuance of Q2 financial results on Monday, August 16, 2010 . , ... Conference Call Information , , ... live conference call via phone, dial (800) 757 8521 from the United States ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Keep Kids, Pets Away From Skin Sprayed With Evamist 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 3
(Date:7/29/2014)... TN (PRWEB) July 29, 2014 The ... the reimbursement model of all hospitals. Studies show that ... One simple, easy, low cost tool that great ... performance by 20 to 25%. , Their secret? Debriefing ... one anther at the end of an operational event. ...
(Date:7/29/2014)... to a more streamlined process for obtaining stem cells, which ... tissue for failing body parts, according to UC San Francisco ... Cell . , The work builds on a strategy ... in which they again have the potential to become any ... may soon increase thanks to the scientists, identification of biochemical ...
(Date:7/29/2014)... 2014 On Friday, the United States ... week of October 12-18, 2014, as "National Case Management ... improving healthcare outcomes for patients. The resolution was introduced ... (R-AR), with support by the Case Management Society of ... case management professionals for their contributions to healthcare. , ...
(Date:7/29/2014)... July 29, 2014 The Eleventh Annual ... Summit concluded with the $10,000 prize being presented to ... http://www.bikanta.com ) , The 11th Annual Summit was held ... entrepreneurs who can bring innovative products and services for ... pleased to have had such excellent array of young ...
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
Breaking Medicine News(10 mins):Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:Silicon Valley Boomer Venture Summit Names Bikanta Competition Winner 2Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2
... WASHINGTON, July 9 The Pharmaceutical Care,Management Association ... the Medicare bill, which includes a provision that ... "The inclusion of an e-prescribing requirement in ... a patient,s perspective, e-prescribing,is the most important issue ...
... Protect Patient Access To Community,Pharmacies, ALEXANDRIA, ... voted by unanimous consent in favor of ... Providers Act of 2008 contains three critical,provisions ... D claims, delayed cuts to Medicaid generic ...
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Counseling for All Combat Veterans, WASHINGTON, July 9 ... in 39 additional,communities across the country where the Department ... 2009., "Community-based Vet Centers -- already in all ... health program," said Dr. James B. Peake,Secretary of Veterans ...
... body,s ability to repair sperm DNA, studies find , , ... over- or underweight can have a negative effect on ... to be presented July 9 at the annual conference ... in Barcelona, Spain. , While semen samples from diabetics ...
... Ind., July 9 Zimmer Holdings, Inc.,(NYSE and SWX: ... conference call will be broadcast live over the Internet ... A news release,detailing the quarterly results will be made ... The live audio webcast can be accessed via ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:VA Vet Centers Coming to 39 Communities 2Health News:Diabetes, Weight Tied to Male Infertility 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Medicine Products: